生命科学资讯

NIH stops low-dose Xarelto arm of large stroke study due to safety concerns

Nektar, continuing comeback, says eczema drug’s effects hold up in follow-up study

Is AstraZeneca on track to meet its $80B revenue target?

FDA rejects Regenxbio treatment in another blow to gene therapy

Waters Corporation (WAT): Guggenheim Reiterates 'Buy' Rating wit - GuruFocus

The fallout from Novo vs. Hims

Planetary microbiome structure and generalist-driven gene flow across disparate habitats

Kailera, Hengrui tout up to 12% weight loss in midstage study for obesity pill

Evommune's Dupixent-like phase 2 eczema data drive 75% stock rally

Merck teams up with British medtech to boost vaginal therapeutics delivery system

AstraZeneca reveals oral GLP-1 scored phase 2 wins but holds back weight loss data

Nektar eczema candidate 'checked all of the boxes' in long-term phase 2 data

2026 kicks off with $10.8B January financing haul

Iambic raises the bard in AI, pens $1.7B Takeda deal

China amends drug rules to enforce lifecycle accountability

AI meets antibody design: Galux draws $29M series B for drug R&D

Innovent-Lilly $8.5B deal signals new China inflection point

Shanghai's Cascade gets $72M to pursue MASH, obesity and diabetes drugs

Waters Completes Combination with BD Biosciences and Diagnostic Solutions Businesses - Chromatography Online

Nektar posts one-year eczema success; Pfizer ends malnutrition trial